145 related articles for article (PubMed ID: 16455807)
1. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate.
Ohashi R; Kamikozawa Y; Sugiura M; Fukuda H; Yabuuchi H; Tamai I
Drug Metab Dispos; 2006 May; 34(5):793-9. PubMed ID: 16455807
[TBL] [Abstract][Full Text] [Related]
2. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.
Cao X; Yu LX; Barbaciru C; Landowski CP; Shin HC; Gibbs S; Miller HA; Amidon GL; Sun D
Mol Pharm; 2005; 2(4):329-40. PubMed ID: 16053336
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion.
Tahara H; Kusuhara H; Fuse E; Sugiyama Y
Drug Metab Dispos; 2005 Jul; 33(7):963-8. PubMed ID: 15821041
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
5. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
[TBL] [Abstract][Full Text] [Related]
6. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
Varma MV; Sateesh K; Panchagnula R
Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate.
Kato M; Nishida A; Aga Y; Kita J; Kudo Y; Narita H; Endo T
Arzneimittelforschung; 1997 Oct; 47(10):1116-24. PubMed ID: 9368705
[TBL] [Abstract][Full Text] [Related]
8. In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
Sharma P; Varma MV; Chawla HP; Panchagnula R
Farmaco; 2005; 60(11-12):874-83. PubMed ID: 16243320
[TBL] [Abstract][Full Text] [Related]
9. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples.
Varma MV; Sarkar M; Kapoor N; Panchagnula R
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Feb; 816(1-2):243-9. PubMed ID: 15664356
[TBL] [Abstract][Full Text] [Related]
10. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine.
Tannergren C; Petri N; Knutson L; Hedeland M; Bondesson U; Lennernäs H
Clin Pharmacol Ther; 2003 Nov; 74(5):423-36. PubMed ID: 14586383
[TBL] [Abstract][Full Text] [Related]
11. Efflux transport of a new quinolone antibacterial agent, HSR-903, across the blood-brain barrier.
Murata M; Tamai I; Kato H; Nagata O; Tsuji A
J Pharmacol Exp Ther; 1999 Jul; 290(1):51-7. PubMed ID: 10381759
[TBL] [Abstract][Full Text] [Related]
12. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Kharasch ED; Hoffer C; Altuntas TG; Whittington D
J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
[TBL] [Abstract][Full Text] [Related]
13. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
Batrakova EV; Miller DW; Li S; Alakhov VY; Kabanov AV; Elmquist WF
J Pharmacol Exp Ther; 2001 Feb; 296(2):551-7. PubMed ID: 11160643
[TBL] [Abstract][Full Text] [Related]
14. The advantages of the Ussing chamber in drug absorption studies.
Gotoh Y; Kamada N; Momose D
J Biomol Screen; 2005 Aug; 10(5):517-23. PubMed ID: 16093561
[TBL] [Abstract][Full Text] [Related]
15. Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine.
Okudaira N; Komiya I; Sugiyama Y
J Pharmacol Exp Ther; 2000 Nov; 295(2):717-23. PubMed ID: 11046110
[TBL] [Abstract][Full Text] [Related]
16. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.
Washington CB; Wiltshire HR; Man M; Moy T; Harris SR; Worth E; Weigl P; Liang Z; Hall D; Marriott L; Blaschke TF
Drug Metab Dispos; 2000 Sep; 28(9):1058-62. PubMed ID: 10950849
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein reduces the ability of amitriptyline metabolites to cross the blood brain barrier in mice after a 10-day administration of amitriptyline.
Grauer MT; Uhr M
J Psychopharmacol; 2004 Mar; 18(1):66-74. PubMed ID: 15107187
[TBL] [Abstract][Full Text] [Related]
18. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine.
Tamai I; Kido Y; Yamashita J; Sai Y; Tsuji A
J Drug Target; 2000; 8(6):383-93. PubMed ID: 11328664
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats.
Kamath AV; Chong S; Chang M; Marathe PH
Cancer Chemother Pharmacol; 2005 Feb; 55(2):110-6. PubMed ID: 15338193
[TBL] [Abstract][Full Text] [Related]
20. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
